Frank McCormick, PhD, FRS
Comprehensive Cancer Center and Cancer Research Institute
University of California
San Francisco, California
Dr. McCormick concentrates his research on the fundamental differences between normal cells and cancer cells, which can lead to the use of naturally occurring and engineered viruses as novel therapeutic strategies. His work has focused on the adenovirus d11520, which lacks a gene that inhibits the p53 tumor protein, and can be exploited to selectively target cancer cells lacking p53.
Cancer Therapy Based on Oncogenes and Tumor Suppressors
Frank McCormick, PhD, FRS, and Cancer Center Director Nicholas Vogelzang, MD